Preclinical (premotor) Parkinson's disease

Area of Science:

• Neurology
• Neuroscience
• Medical Imaging

Background:

• Parkinson's disease (PD) involves dopaminergic cell loss, potentially due to oxidative stress.
• Current treatments focus on symptoms, but neuroprotection is emerging.
• Early detection of preclinical PD is vital for effective neuroprotective therapies.

Purpose of the Study:

• To identify individuals in the preclinical or very early stages of Parkinson's disease.
• To evaluate the utility of olfactory testing and [123I]beta-CIT SPECT imaging for early PD diagnosis.
• To assess early, non-motor symptoms in first-degree relatives of PD patients.

Main Methods:

• An epidemiological study involving 500 first-degree relatives of PD patients.
• Assessment of early non-motor symptoms: olfactory disturbances, neurocognitive dysfunction, visuomotor control, mood, and personality disorders.
• [123I]beta-CIT single photon emission computed tomography (SPECT) imaging in subjects with extreme olfactory function (top 10% and bottom 10%).

Main Results:

• The study design and initial data from an ongoing investigation are presented.
• Olfactory disturbances and subtle neurocognitive deficits are potential early indicators of PD.
• [123I]beta-CIT SPECT imaging shows promise for diagnosing preclinical PD.

Conclusions:

• Early identification of Parkinson's disease is feasible through the assessment of non-motor symptoms and advanced imaging techniques.
• Olfactory testing combined with [123I]beta-CIT SPECT imaging may aid in detecting preclinical PD.
• Further research is ongoing to validate these findings in a larger cohort.